Brooklyn ImmunoTherapeutics to Participate in Grand Opening of Cambridge-Based mRNA Cleanroom Facility Shared with Factor Bioscience

September 15, 2021

NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) – Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that Chief Executive Officer and President Howard J. Federoff, M.D., Ph.D., will participate in the grand opening and ribbon cutting ceremony for its mRNA Cleanroom facility shared with Factor Bioscience in Cambridge, Mass.

The new mRNA Cleanroom facility is an important part of our planned R&D operations, and of strategic advantage as we share the space with Factor Biosciences, from which we have in-licensed critical mRNA and gene editing technology” said Dr. Federoff. “We are also pleased to wish Factor Bioscience and its co-founders, Drs. Matt Angel and Christopher Rohde, a happy tenth anniversary of the founding of that company.”